Paradigm Therapeutics, Inc. nominada al prestigioso premio Prix Galien USA 2026 "Best Start-Up"

SD-101 (Zorblesia™)Positive

AI Analysis

Summary

Paradigm Therapeutics has been nominated for the second consecutive year for the Prix Galien USA 2026 Best Start-Up award for its topical therapy SD-101 (Zorblesia™) for epidermolysis bullosa.

Outcome Details

Nomination for Prix Galien USA 2026 Best Start-Up award

Importance:2/10

Sentiment:

0.60

award nominationtopical therapyepidermolysis bullosastart-up

Read the original article

Published by PR Newswire Pharma on October 14, 2026 3:58 PM

Read Original